ArticleJournal of pain research2025
The Neural Mechanisms of rTMS and Placebo Effects in Trigeminal Neuralgia: Evidence From fMRI Network Dynamics.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Repetitive transcranial magnetic stimulation (rTMS) has been suggested to possess analgesic properties, yet its efficacy in treating trigeminal neuralgia (TN) remains uncertain. Methods: In this randomized, double-blind trial, thirty-four patients were randomly allocated to one of three groups: active M1-targeted rTMS, sham stimulation, or active stimulation of the dorsolateral prefrontal cortex (dlPFC) as a control. The treatment protocol spanned two weeks, consisting of two 5-day stimulation sessions separated by a 2-day interval. MRI and clinical outcomes (VAS, Hamilton Anxiety/Depression Scales) were assessed pre-/post-intervention and at one-month follow-up. Results: Significant reductions in pain, anxiety, and depression occurred across all groups. Neuroimaging revealed decreased insular cortex activation universally, while increased frontal lobe activity emerged specifically in sham and control groups. Notably, no intergroup differences in clinical outcomes were observed despite distinct neural pathways, specifically involving the insula rather than the prefrontal cortex. Conclusion: In the active rTMS group, clinical improvements were associated with modulation of the insula, reflecting targeted neurophysiological effects. In contrast, improvements in the sham group were linked to increased prefrontal and orbitofrontal cortex activation, consistent with placebo-related mechanisms. Significance: This study unveils the critical role of cognitive-emotional pathways in rTMS efficacy, urging integration of neurobiological and psychological strategies for TN therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.